Daxor Corporation is seeking approval from the US Food and Drug Administration (FDA) for its next-generation blood volume analyser, Daxor BVA.
Daxor BVA is designed for rapid, simple, and bedside patient care.
The company submitted to the FDA through the 510(k)/CLIA-waiver dual pathway, with potential clearance for the analyser anticipated in the first half of this year.
Daxor CEO and president Michael Feldschuh said: “Today marks a long-anticipated and momentous milestone in our continued commitment to our customers and patients, and to achieving our vision of optimal blood volume for all.
